检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:刘俊江[1] 张蕴霞[2] 李瑾宜[1] 李连印[1] 李守宾[1] 高双友[1]
机构地区:[1]河北省唐山市开滦矿务局总医院泌尿外科,河北唐山063006 [2]河北省唐山市开滦矿务局总医院妇产科,河北唐山063006
出 处:《现代生物医学进展》2012年第7期1309-1311,1305,共4页Progress in Modern Biomedicine
摘 要:目的:探讨抑癌基因p16、细胞周期蛋白cyclin D1和凋亡抑制基因survivin在膀胱移行细胞癌中的表达及意义。方法:膀胱移行细胞癌组67例,10例正常正常膀胱粘膜作为对照,采用免疫组织化学方法检测p16和cyclin D1、survivin蛋白表达,然后分析上述三种蛋白在膀胱癌组织中的表达情况,以及随着不同临床分期和病理分级表达的变化。结果:所有膀胱癌患者平均年龄58.16岁,其中男性患者38例。免疫组织化学分析表明,p16和cyclin D1、survivin蛋白均表达在细胞的细胞核。膀胱癌组织中P16表达明显低于正常对照组,而cyclin D1和survivin表达明显高于正常对照组。随着临床分期的进展,p16表达明显下降,cyclinD1表达明显上升;而随着膀胱癌病理分级升高,p16表达明显下降,survivin表达上升。此外,膀胱癌组织中,p16与cyclin D1p16之间存在着明确的负相关。结论:p16、cyclin D1、survivin在膀胱移行细胞癌的生物学行为中起重要作用,p16,cyclin D1和survivin与膀胱移行细胞癌的恶性进展有关。Objective: To investigate the expression of p16,cyclin D1 or survivin as well as the clinical significance in transitional cell carcinoma of bladder.Methods: 67 specimens were derived by surgical operation.p16 protein,cyclin D1 and survivin were investigated by immunohistochemical method.Results: 67 patients with transitional cell carcinoma of bladder were enrolled in the study,with mean age of 58.16 years.38 cases were men.The expression of p16 was significant lower than the normal controls,and the expression of cyclin D1 and survivin were much higher than the normal controls.With the clinical stage progressed,the p16 expression level down-regulated,and cyclin D1 up-regulated;while with the tumor grade increased,the p16 expression down-regulated,and the survivin expression up-regulated.Moreover,the expression of p16 was negatively correlated to the expression of cyclin D1.Conclusions: p16,cyclin D1 and survivin play an important role in the behavior of biochemical in TCC.The expression of p16,cyclin D1 and survivin all involved in the progress of transitional cell carcinoma of bladder.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.44